Sanofi (SNYN) Stock Price & Analysis
SNYN Stock Chart & Stats
- Day’s Range
- MXN 808.08 - MXN 857.99
- 52-Week Range
- MXN 700.00 - MXN 1,050.00
- Previous Close
- MXN 808.08
- Volume
- 0
- Average Volume (3M)
- 43
- Market Cap
- MXN 2.01T
- Enterprise Value
- MXN 122.96B
- Total Cash (Recent Filing)
- MXN 6.35B
- Total Debt (Recent Filing)
- MXN 23.58B
- Price to Earnings (P/E)
- 24.4
- Beta
- 0.12
- Next Earnings
- Jan 28, 2027 (Est.)
- EPS Estimate
- 19.21
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 5.52%
Bulls Say, Bears Say
Bulls Say
Dupixent Scale And Durable Demand
Dupixent combines substantial patient adoption with strong volume-led growth across indications and geographies. This scale supports durable commercial momentum, while broader use can strengthen Sanofi’s specialty-care base and provide an important foundation for future portfolio expansion.
Growing Pharmaceutical Launch Portfolio
Rapid growth from Ayvakit, ALTUVIIIO, Sarclisa, Wayrilz and Qfitlia indicates that newer products are increasingly contributing to revenue. A broadening launch portfolio can reduce reliance on mature medicines and support sustained growth as additional treatments gain patient adoption.
Conservative Balance Sheet
Moderate leverage and substantial equity provide financial flexibility for research, launches, partnerships and other strategic investments. This balance-sheet strength should help Sanofi absorb operating volatility while preserving capacity to fund its long-term pharmaceutical and vaccine businesses.
Bears Say
Structural Vaccine Growth Pressure
The weaker vaccine outlook reflects more than a single quarter, citing lower U.S. vaccination coverage and pressure across respiratory and pediatric vaccines. Persistent demand and market-access challenges could constrain growth in a major business segment and reduce portfolio balance.
Pipeline Execution Setbacks
Multiple late-stage failures and discontinuations reduce the probability that research spending converts into future products and revenue. They also increase the importance of business development and successful prioritization, while making the long-term replacement of aging medicines less certain.
Uneven Profitability And Cash Conversion
Revenue growth has not translated consistently into operating profit or cash generation, indicating pressure from costs, margins or earnings mix. Uneven conversion reduces financial predictability and can limit confidence in the durability of reported growth over coming quarters.
Sanofi News
Sanofi’s New Oral Alzheimer’s Drug Enters Mid-Stage Trials: What Investors Should Watch
Sanofi SA ($SNY) announced an update on their ongoing clinical study. Sanofi is running a mid-stage study called “A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and
SNYN FAQ
What was Sanofi’s price range in the past 12 months?
What is Sanofi’s market cap?
When is Sanofi’s upcoming earnings report date?
How were Sanofi’s earnings last quarter?
Is Sanofi overvalued?
Does Sanofi pay dividends?
What is Sanofi’s EPS estimate?
How many shares outstanding does Sanofi have?
What happened to Sanofi’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sanofi?
What is the TipRanks Smart Score and how is it calculated?
Sanofi Stock Smart Score
Company Description
Sanofi
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Belén Garijo López
- Employees
- 76,493
- Website
- www.sanofi.com
- Address
- 46, avenue de la Grande ArmEe, Paris, IF, 75017, FR
Sanofi (SNYN) Earnings & Revenues
SNYN Company Deck
SNYN Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, supported by strong Q2 sales, EPS and margin growth, an upgraded 2026 outlook, robust Dupixent performance, launch momentum, rare disease growth and several regulatory and pipeline achievements. However, management acknowledged meaningful challenges, including expected second-half deceleration, declining vaccine sales, weaker U.S. vaccination coverage, pipeline failures and discontinuations, an ongoing R&D transformation, weaker China momentum and future one-off-related BOI headwinds. The highlights significantly outweighed the lowlights.
View all MX:SNYN earnings summariesSNYN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 3 | 4 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 12 | 0 | 0 |
